CHALFONT ST GILES, UK – 3 October 2014 – GE Healthcare Life Sciences (NYSE:GE) announced today that the company has been shortlisted as a finalist for four BioProcess International (BPI) Awards1. These prestigious awards, which are voted for by experts in the field and supported by bioprocess specialist publication BioProcess International – celebrate and recognize […]
Important risk factor for breast cancer still not widely-known: only one out of five people globally has seen, heard or read about dense breast tissue in the last six months Countries with low awareness that dense breast tissue is an increased risk factor for developing breast cancer include UK, USA, Japan and South Korea – […]
Allegheny, PA, October 1, 2014 — Allegheny Health Network is the first center in the nation to install SenoClaire*, GE Healthcare’s (NYSE: GE) new breast tomosynthesis solution designed with a three-dimensional imaging technology. SenoClaire, which was approved by the FDA earlier this month, uses a low-dose short X-ray sweep around the positioned breast with nine […]
SPOKANE, OCTOBER 01, 2014 -– Asuris announces its suite of 2015 Medicare products, including PPO plans with lower primary care physician (PCP) and specialist co-pays in network. “Affordability is a top priority for our members, and we offer plans with a range of choice and price options,” said Lisa Brubaker, vice president of Government Programs […]
Aliso Viejo, CA – September 30, 2014 – GE Healthcare today announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration […]
Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone Phase III coBRIM study results will be presented today during the Presidential Symposium at the European Society of Medical Oncology (ESMO) 2014 Congress and published in the New England Journal of Medicine Roche has submitted an EU marketing authorisation application […]
Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and chemotherapy1 Median overall survival of almost five years is the longest observed to date in people […]
Program expands access to care supporting the Diagnostics Access Iniative Basel, 26 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Global Access Program for HIV viral load testing, created in partnership with UNAIDS, the joint United Nations Program on HIV/AIDS, the Clinton Health Access Initiative (CHAI), the […]
U.S. and EU Filings Planned for Q4 2014 FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 24, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives. The […]
12-Week Course of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) in Japanese Phase 3 Study Ledipasvir/Sofosbuvir Simplifies Hepatitis C Treatment to a Single, Once-Daily Tablet FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 24, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency […]